Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis

NCT00035256 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

330

Enrollment

INDUSTRY

Sponsor class

Conditions

Osteoporosis, Postmenopausal

Interventions

DRUG: teriparatide
DRUG: raloxifene HCl
DRUG: placebo

Sponsor

Eli Lilly and Company